Stay updated on Daratumumab & DLI for Relapsed AML Clinical Trial
Sign up to get notified when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.

Latest updates to the Daratumumab & DLI for Relapsed AML Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedAdded a Locations section showing the study site in Columbus, Ohio. Removed the previous Ohio Locations entry; page revision updated to v3.3.3.SummaryDifference0.2%

- Check29 days agoNo Change Detected
- Check50 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; no study details appear to be changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check58 days agoChange DetectedThe bottom notice about government funding and operating status was removed, with no changes to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check72 days agoChange DetectedNo significant changes detected between the two screenshots; only minor formatting adjustments to the study details page, and to avoid alerts for small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check101 days agoChange DetectedIntroducing a major update notice and current operating status guidance, along with a new version tag v3.2.0; the old version tag v3.1.0 has been removed.SummaryDifference3%

- Check108 days agoChange DetectedUpdate: version changed from v3.0.2 to v3.1.0; reflects a new release.SummaryDifference0.1%

Stay in the know with updates to Daratumumab & DLI for Relapsed AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.